Caribou Biosciences’ (CRBU) Hold Rating Reiterated at Brookline Capital Markets

Caribou Biosciences (NASDAQ:CRBU)‘s stock had its “hold” rating restated by equities research analysts at Brookline Capital Markets in a research note issued on Wednesday, Benzinga reports.

Several other research analysts have also commented on CRBU. Bank of America reduced their price target on Caribou Biosciences from $6.00 to $5.00 and set a “buy” rating for the company in a research report on Friday, August 14th. Wall Street Zen lowered Caribou Biosciences from a “hold” rating to a “sell” rating in a research note on Saturday, September 19th. Royal Bank Of Canada downgraded shares of Caribou Biosciences from an “outperform” rating to a “sector perform” rating and set a $1.00 target price for the company. in a report on Wednesday. Leerink Partners reissued a “market perform” rating and set a $1.00 price target (down from $4.00) on shares of Caribou Biosciences in a research report on Wednesday. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Caribou Biosciences in a report on Friday, July 17th. One investment analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, three have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $5.50.

Caribou Biosciences Stock Down 43.1%

CRBU stock traded down $0.49 during trading on Wednesday, hitting $0.65. 19,179,505 shares of the company’s stock traded hands, compared to its average volume of 1,568,795. The firm has a market capitalization of $69.26 million, a P/E ratio of -0.60 and a beta of 2.31. The business has a fifty day simple moving average of $1.47 and a two-hundred day simple moving average of $1.76. Caribou Biosciences has a 1 year low of $0.55 and a 1 year high of $3.54.

Caribou Biosciences (NASDAQ:CRBU) last posted its earnings results on Thursday, August 13th. The company reported ($0.24) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.32) by $0.08. The company had revenue of $1.50 million during the quarter, compared to analyst estimates of $2.28 million. Caribou Biosciences had a negative return on equity of 89.11% and a negative net margin of 1,030.42%. On average, equities research analysts predict that Caribou Biosciences will post -0.88 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the business. Spark Investment Management LLC purchased a new stake in Caribou Biosciences in the second quarter valued at about $42,000. Public Employees Retirement System of Ohio purchased a new stake in shares of Caribou Biosciences during the second quarter worth about $69,000. Bank of America Corp DE acquired a new position in shares of Caribou Biosciences during the second quarter valued at about $2,483,000. Man Group plc acquired a new position in shares of Caribou Biosciences during the second quarter valued at about $423,000. Finally, Hsbc Holdings PLC purchased a new position in shares of Caribou Biosciences in the 2nd quarter valued at approximately $62,000. 77.51% of the stock is owned by institutional investors and hedge funds.

About Caribou Biosciences

Caribou Biosciences, Inc is a clinical-stage biotechnology company developing genome-edited cell therapies for cancer and other serious diseases. The company uses its proprietary CRISPR-based chRDNA genome-editing platform to engineer immune cells, with an emphasis on allogeneic, or “off-the-shelf,” CAR-T therapies designed to target tumors without requiring cells to be collected from each individual patient.

Caribou’s research and development programs have focused primarily on hematologic malignancies, including investigational CAR-T candidates directed at targets such as CD19 and BCMA.